CA_logo-blueCaring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

  July 2012

Clinical Trials, Cohort Studies, Pilot Studies

Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3. Vigani AG, Gonçales ES, Pavan MH, et al. Braz J Infect Dis. 2012 Jun;16(3):232-6.

http://www.ncbi.nlm.nih.gov/pubmed/22729189.1

Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. Suzuki F, Sezaki H, Akuta N, et al. J Clin Virol. 2012 Jun 1. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22658798.1

Association of Serum Adipocytokines With Insulin Resistance and Liver Injury in Patients With Chronic Hepatitis C Genotype 4. Khattab MA, Eslam M, et al. J Clin Gastroenterol. 2012 Jun 1. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22664476.1

Finasteride and Methadone Use and Risk of Advanced Hepatitis C Related Liver Disease.

White DL, Hashmi A, Ramsey DJ, et al. Dig Dis Sci. 2012 Jun 5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22669204.1

Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C.

Christensen PB, Krarup HB, Laursen AL, et al. Scand J Gastroenterol. 2012 Jun 7. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22670704.1

Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1. Palmer M, Rubin R, Rustgi V; Taribavirin Viral Kinetic Study Group. Aliment Pharmacol Ther. 2012 Jun 19. doi: 10.1111/j.1365-2036.2012.05188.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22708649.1

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.

Pol S, Ghalib RH, Rustgi VK, et al. Lancet Infect Dis. 2012 Jun 15. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22714001.1

Inflammation biomarkers in chronic hepatitis C: association with liver histopathology, HCV genotype and cryoglobulinemia. Atta M, Cabral M, Santos G, Paraná R, Atta A. Inflamm Res. 2012 Jun 21. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22718074.1

Mechanism of thrombocytopenia in chronic hepatitis C as evaluated by the immature platelet fraction. Zucker ML, Hagedorn CH, Murphy CA, Stanley S, Reid KJ, Skikne BS. Int J Lab Hematol. 2012 Jun 18. doi: 10.1111/j.1751-553X.2012.01429.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22708981.1

Basic and Applied Science, Pre-Clinical Studies

Elevated Serum Osteopontin Levels in Chronic Hepatitis C Virus Infection: Association with Autoimmune Rheumatologic Manifestations. Bassyouni IH, Bassyouni RH, Ibrahim NH, Soliman AF. J Clin Immunol. 2012 Jun 24. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22730056.1

Identification and analysis of hepatitis C virus NS3 helicase inhibitors using nucleic acid binding assays. Mukherjee S, Hanson AM, Shadrick WR, et al. Nucleic Acids Res. 2012 Jun 27. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22740655.1

FOXO3 Regulates the CD8 T cell Response to a Chronic Viral Infection. Sullivan JA, Kim EH, Plisch EH, Suresh M. J Virol. 2012 Jun 6. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22675000.1

Interferon-γ Stimulated Genes, but not USP18, are Expressed in Livers of Patients with Acute Hepatitis C. Dill MT, Makowska Z, Duong FH, et al. Gastroenterology. 2012 Jun 4. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22677194.1

Hepatitis C virus E2 protein involve in insulin resistance through an impairment of Akt/PKB and GSK3ß signaling in hepatocytes. Hsieh MJ, Lan KP, Liu HY, Zhang XZ, Lin YF, Chen TY, Chiou HL. BMC Gastroenterol. 2012 Jun 21;12(1):74. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22721429.1

BACKGROUND: Hepatitis C virus (HCV) infection may cause liver diseases of various severities ranging from primary acute infection to life-threatening diseases, such as cirrhosis or hepatocellular carcinoma with poor prognosis. According to clinical findings, HCV infection may also lead to some extra-hepatic symptoms, including type 2 diabetes mellitus (DM). Since insulin resistance is the major etiology for type 2 DM and numerous evidences showed that HCV infection associated with insulin resistance, the involvement of E2 in the pathogenesis of type 2 DM and underlying mechanisms were investigated in this study. RESULTS:  Results showed that E2 influenced on protein levels of insulin receptor substrate-1 (IRS-1) and impaired insulin-induced Ser308 phosphorylation of Akt/PKB and Ser9 phosphorylation of GSK3beta in Huh7 cells, leading to an inhibition of glucose uptake and glycogen synthesis, respectively, and eventually insulin resistance. CONCLUSIONS: Therefore, HCV E2 protein indeed involved in the pathogenesis of type 2 DM by inducing insulin resistance.

Genotyping and resistance profile of Hepatitis C (HCV) genotypes 1 to 6 by sequencing the NS3 protease region using a single optimized sensitive method. Bernard B, Marianne CB, Nathalie B, et al. J Virol Methods. 2012 Jun 20. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22728274.1

Trans-complemented hepatitis C virus particles as a versatile tool for study of virus assembly and infection. Suzuki R, Saito K, Kato T, et al. Virology. 2012 Jun 22. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22727832.1

Investigation of residual hepatitis C virus in presumed recovered subjects.

Fujiwara K, Allison RD, Wang RY, et al. Hepatology. 2012 Jun 23. doi: 10.1002/hep.25921. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22729600.1

HIV/HCV Coinfection

Differences in Virological Response to Peginterferon-α Plus Ribavirin in HIV-Positive Patients Coinfected With HCV Subtypes 1a or 1b. Rallón NI, Pineda JA, Soriano V, et al. J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):117-23.

http://www.ncbi.nlm.nih.gov/pubmed/22362153.1

Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/HCV co-infected patients. Hull MW, Rollet K, Moodie EE, et al. AIDS. 2012 Jun 26. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22739388.1

Role of GB Virus C in Human Immunodeficiency Virus Type-1- and Hepatitis C Virus-infected Hemophiliac Children and Adolescents. Tenckhoff S, Kaiser T, Bredeek F, et al. J Acquir Immune Defic Syndr. 2012 Jun 13. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22706293.1

IL28B CC Genotype Is Associated with Higher All-Cause Mortality in Antiretroviral-Treated HIV-Infected Patients. Parczewski M, Bander D, Leszczyszyn-Pynka M, et al. AIDS Res Hum Retroviruses. 2012 Jun 4. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22545770.1

Different impact of IL28B polymorphisms on response to peginterferon-α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b. Vispo E, Rallon NI, Labarga P, Barreiro P, Benito JM, Soriano V. J Clin Virol. 2012 Jun 20. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22727259.1

CD4(+) and CD8(+) regulatory T cells (Tregs) are elevated and display an active phenotype in patients with chronic HCV mono-infection and HIV/HCV co-infection. Hartling HJ, Gaardbo JC, Ronit A, et al. Scand J Immunol. 2012 Jun 4. doi: 10.1111/j.1365-3083.2012.02725.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22671952.1

Epidemiology, Diagnostics, and Miscellaneous Works

Estimates of the Population Prevalence of Injection Drug Users among Hispanic Residents of Large US Metropolitan Areas. Pouget ER, Friedman SR, Cleland CM, Tempalski B, Cooper HL. J Urban Health. 2012 Jun;89(3):527-64.

http://www.ncbi.nlm.nih.gov/pubmed/22411420.1

A Population-Based Study of the Epidemiology of Hepatitis C in a North American Population. Julia U, Bruce TR, Douglas T, Yossel MG. J Hepatol. 2012 Jun 2. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22668641.1

Determination of optimized multidisciplinary care team for maximal antiretroviral therapy adherence. Horberg MA, Hurley LB, Towner WJ, et al. J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):183-90.

http://www.ncbi.nlm.nih.gov/pubmed/22293551.1

The Burden of Untreated Hepatitis C Virus Infection: A US Patients' Perspective. El Khoury AC, Vietri J, Prajapati G. Dig Dis Sci. 2012 Jun 5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22674399.1

Liver Cancer

Limitation of repeated radiofrequency ablation in hepatocellular carcinoma: Proposal of a three (times) ×  3 (years) index.

Yokoyama K, Anan A, Iwata K, et al. J Gastroenterol Hepatol. 2012 Jun;27(6):1044-50. doi: 10.1111/j.1440-1746.2012.07134.x.

http://www.ncbi.nlm.nih.gov/pubmed/22433056.1

Resection of hepatocellular carcinoma without cirrhosis. Shrager B, Jibara G, Schwartz M, Roayaie S. Ann Surg. 2012 Jun;255(6):1135-43.

http://www.ncbi.nlm.nih.gov/pubmed/22258064.1

MAGE-4 gene m-RNA and TGF in blood as potential biochemical markers for HCC in HCV-infected patients. Hussein YM, Morad FE, Gameel MA, et al. Med Oncol. 2012 Jun 1. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22653756.1

Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma: Clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection. Li T, Qin LX, Gong X, et al. Cancer. 2012 Jun 26. doi: 10.1002/cncr.27697. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22736338.1